Protocatechuic aldehyde protects against isoproterenol-induced cardiac hypertrophy via inhibition of the JAK2/STAT3 signaling pathway-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Protocatechuic aldehyde protects against isoproterenol-induced cardiac hypertrophy via inhibition of the JAK2/STAT3 signaling pathway

Published:2018-08-21 Issue:12 Volume:391 Page:1373-1385
ISSN:0028-1298
Container-title:Naunyn-Schmiedeberg's Archives of Pharmacology
language:en
Short-container-title:Naunyn-Schmiedeberg's Arch Pharmacol

Author:

Fang Xiuli,Liu Yajun,Lu Jing,Hong Huiqi,Yuan Jing,Zhang Yuhong,Wang Panxia,Liu Peiqing,Ye Jiantao^ORCID

Funder

National Natural Science Foundation of China (CN)

National Natural Science Foundation of China

Team item of the Natural Science Foundation of Guangdong Province

Major Project of Guangdong Provincial Department of Science and Technology

Major Project of Platform Construction Education Department of Guangdong Province

Special Program for Applied Science and Technology of Guangdong Province

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,General Medicine

Link

http://link.springer.com/article/10.1007/s00210-018-1556-7/fulltext.html

Reference48 articles.

1. Al-Rasheed NM et al (2015) Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway. Drug Des Devel Ther 9:3217–3229. https://doi.org/10.2147/Dddt.S86431

2. Balakumar P, Jagadeesh G (2010) Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared? Pharmacol Res 62:365–383

3. Beckles DL, Mascareno E, Siddiqui MA (2006) Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy. Vasc Pharmacol 45:350–357. https://doi.org/10.1016/j.vph.2006.05.006

4. Bisping E, Wakula P, Poteser M, Heinzel FR (2014) Targeting cardiac hypertrophy: toward a causal heart failure therapy. J Cardiovasc Pharmacol 64:293–305. https://doi.org/10.1097/FJC.0000000000000126

5. Booz GW, Day JNE, Baker KM (2002) Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol 34:1443–1453. https://doi.org/10.1006/jmcc.2002.2076

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Danshen-Shanzha formula for the treatment of atherosclerosis: ethnopharmacological relevance, preparation methods, chemical constituents, pharmacokinetic properties, and pharmacological effects;Frontiers in Pharmacology;2024-06-07

2. Modulation of the c-JNK/p38-MAPK signaling pathway: Investigating the therapeutic potential of natural products in hypertension;Phytomedicine Plus;2024-05

3. Targeting the JAK2/STAT3 signaling pathway with natural plants and phytochemical ingredients: A novel therapeutic method for combatting cardiovascular diseases;Biomedicine & Pharmacotherapy;2024-03

4. Lipid regulation of protocatechualdehyde and hydroxysafflor yellow A via AMPK/SREBP2/PCSK9/LDLR signaling pathway in hyperlipidemic zebrafish;Heliyon;2024-02

5. Unraveling the role of Xist RNA in cardiovascular pathogenesis;Pathology - Research and Practice;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3